サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：一次性進行型多発性硬化症治療薬の世界市場 (2022-2031年)：薬剤タイプ (承認済み薬・パイプライン薬)・流通チャネル (小売薬局・Eコマース) 別の市場規模・シェア・成長・動向・予測
市場調査レポート
商品コード
1208547

一次性進行型多発性硬化症治療薬の世界市場 (2022-2031年)：薬剤タイプ (承認済み薬・パイプライン薬)・流通チャネル (小売薬局・Eコマース) 別の市場規模・シェア・成長・動向・予測

Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs & Pipeline Drugs; & Distribution Channel: Retail Pharmacies, E-commerce, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
一次性進行型多発性硬化症治療薬の世界市場 (2022-2031年)：薬剤タイプ (承認済み薬・パイプライン薬)・流通チャネル (小売薬局・Eコマース) 別の市場規模・シェア・成長・動向・予測
出版日: 2022年12月13日
発行: Transparency Market Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の一次性進行型多発性硬化症治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、パイプライン分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の一次性進行型多発性硬化症治療薬市場

第4章 市場概要

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の一次性進行型多発性硬化症治療薬市場の分析・予測
  • ポーターのファイブフォース分析

第5章 主な洞察

  • 主なM&A
  • パイプライン分析
  • 主要国における疾患有病率・発生率
  • 主要製品/ブランド分析
  • 主な研究機関
  • COVID-19の産業への影響（バリューチェーンと短期・中期・長期の影響）

第6章 世界の一次性進行型多発性硬化症治療薬市場の分析・予測：薬剤タイプ別

  • イントロダクション・定義
  • 主な調査結果/展開
  • 市場予測
    • 承認薬
    • パイプライン薬
  • 市場の魅力

第7章 世界の一次性進行型多発性硬化症治療薬市場の分析・予測：流通チャネル別

  • イントロダクション・定義
  • 主な調査結果/展開
  • 市場予測
    • 小売薬局
    • eコマース
    • その他
  • 市場の魅力

第8章 世界の一次性進行型多発性硬化症治療薬市場の分析・予測：地域別

  • 主な調査結果
  • 市場予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力

第9章 北米の一次性進行型多発性硬化症治療薬市場の分析・予測

第10章 欧州の一次性進行型多発性硬化症治療薬市場の分析・予測

第11章 アジア太平洋の一次性進行型多発性硬化症治療薬市場の分析・予測

第12章 ラテンアメリカの一次性進行型多発性硬化症治療薬市場の分析・予測

第13章 中東およびアフリカの一次性進行型多発性硬化症治療薬市場の分析・予測

第14章 競合情勢

  • 参入企業：競合マトリックス (ティア・規模別)
  • 企業シェア分析
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Mapi Pharma Ltd.
    • Atara Biotherapeutics
    • Takeda Pharmaceuticals International, Inc.
    • AB Science
    • Mallinckrodt
図表

List of Tables

  • Table 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 05: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 08: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 17: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 03: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 04: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 05: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 06: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Region, 2021 and 2031
  • Figure 07: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 08: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 10: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 11: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 12: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 13: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country, 2021 and 2031
  • Figure 14: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 15: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 17: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 18: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 19: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 20: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 21: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 22: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 24: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 25: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 26: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 28: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 29: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 31: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 32: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 33: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 34: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 35: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 38: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 39: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 40: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 41: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 42: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 43: Global Primary Progressive Multiple Sclerosis Treatment Market Share Analysis/Ranking, by Company, 2021
目次
Product Code: TMRGL85270

The report provides revenue of the global primary progressive multiple sclerosis treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global primary progressive multiple sclerosis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the primary progressive multiple sclerosis treatment market.

The report delves into the competitive landscape of the global primary progressive multiple sclerosis treatment market. Key players operating in the global primary progressive multiple sclerosis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global primary progressive multiple sclerosis treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Key Mergers & Acquisitions
  • 5.2. Pipeline Analysis
  • 5.3. Disease Prevalence & Incidence Rate globally with key countries
  • 5.4. Key Product/Brand Analysis
  • 5.5. Major Research Institutes Involved
  • 5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2017 - 2031
    • 6.3.1. Approved Drugs
    • 6.3.2. Pipeline Drugs
  • 6.4. Market Attractiveness By Drug Type

7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 7.3.1. Retail Pharmacies
    • 7.3.2. E-commerce
    • 7.3.3. Others
  • 7.4. Market Attractiveness By Distribution Channel

8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast By Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness By Country/Region

9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 9.2.1. Approved Drugs
    • 9.2.2. Pipeline Drugs
  • 9.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 9.3.1. Retail Pharmacies
    • 9.3.2. E-commerce
    • 9.3.3. Others
  • 9.4. Market Value Forecast By Country, 2017 - 2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 10.2.1. Approved Drugs
    • 10.2.2. Pipeline Drugs
  • 10.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 10.3.1. Retail Pharmacies
    • 10.3.2. E-commerce
    • 10.3.3. Others
  • 10.4. Market Value Forecast By Country, 2017 - 2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country

11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 11.2.1. Approved Drugs
    • 11.2.2. Pipeline Drugs
  • 11.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 11.3.1. Retail Pharmacies
    • 11.3.2. E-commerce
    • 11.3.3. Others
  • 11.4. Market Value Forecast By Country, 2017 - 2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country

12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 12.2.1. Approved Drugs
    • 12.2.2. Pipeline Drugs
  • 12.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 12.3.1. Retail Pharmacies
    • 12.3.2. E-commerce
    • 12.3.3. Others
  • 12.4. Market Value Forecast By Country, 2017 - 2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country

13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 13.2.1. Approved Drugs
    • 13.2.2. Pipeline Drugs
  • 13.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 13.3.1. Retail Pharmacies
    • 13.3.2. E-commerce
    • 13.3.3. Others
  • 13.4. Market Value Forecast By Country, 2017 - 2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis By Company (2021)
  • 14.3. Company Profiles
    • 14.3.1. F. Hoffmann-La Roche Ltd.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Sanofi
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Mapi Pharma Ltd.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Atara Biotherapeutics
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Takeda Pharmaceuticals International, Inc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. AB Science
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Mallinckrodt
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis